These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38545756)

  • 1. Novel peripheral blood mononuclear cell mRNA signature for IFN-beta therapy responsiveness prediction in multiple sclerosis.
    Xue Y; Yin P; Chen H; Li G; Zhong D
    Autoimmunity; 2024 Dec; 57(1):2332340. PubMed ID: 38545756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
    van Baarsen LG; Vosslamber S; Tijssen M; Baggen JM; van der Voort LF; Killestein J; van der Pouw Kraan TC; Polman CH; Verweij CL
    PLoS One; 2008 Apr; 3(4):e1927. PubMed ID: 18382694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.
    Hecker M; Thamilarasan M; Koczan D; Schröder I; Flechtner K; Freiesleben S; Füllen G; Thiesen HJ; Zettl UK
    Int J Mol Sci; 2013 Aug; 14(8):16087-110. PubMed ID: 23921681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis.
    Tacke S; Braune S; Rovituso DM; Ziemssen T; Lehmann PV; Dikow H; Bergmann A; Kuerten S
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33707177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Suitable Reference Genes for Peripheral Blood Mononuclear Cell Subset Studies in Multiple Sclerosis.
    Oturai DB; Søndergaard HB; Börnsen L; Sellebjerg F; Christensen JR
    Scand J Immunol; 2016 Jan; 83(1):72-80. PubMed ID: 26395032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
    Goertsches RH; Hecker M; Koczan D; Serrano-Fernandez P; Moeller S; Thiesen HJ; Zettl UK
    Pharmacogenomics; 2010 Feb; 11(2):147-61. PubMed ID: 20136355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of IFN-beta1a treatment alone or associated with pentoxifylline in patients with relapsing-remitting multiple sclerosis (RRMS).
    Pede PD; Visintini D; Telera A; Cucurachi L; Campanini C; Immovilli P; Vescovini R; Sansoni P
    J Interferon Cytokine Res; 2005 Aug; 25(8):485-9. PubMed ID: 16108731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
    Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
    Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.
    Boppana S; Mindur JE; Balashov KE; Dhib-Jalbut S; Ito K
    J Neuroimmunol; 2013 Dec; 265(1-2):68-74. PubMed ID: 24200257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Connection of miR-185 and miR-320a expression levels with response to interferon-beta in multiple sclerosis patients.
    Mousavi SR; Tahmasebivand M; Khorrami M; Ayromlou H; Khalili SK; Khorvash F; Rikhtegar R; Khademi B; Bahmanpour Z; Emamalizadeh B
    Mult Scler Relat Disord; 2020 Sep; 44():102264. PubMed ID: 32554287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.
    Christophi GP; Christophi JA; Gruber RC; Mihai C; Mejico LJ; Massa PT; Jubelt B
    J Neurol Sci; 2011 Aug; 307(1-2):41-5. PubMed ID: 21658727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
    Aliaga-Gaspar P; Hurtado-Guerrero I; Ciano-Petersen NL; Urbaneja P; Brichette-Mieg I; Reyes V; Rodriguez-Bada JL; Alvarez-Lafuente R; Arroyo R; Quintana E; Ramió-Torrentà L; Alonso A; Leyva L; Fernández O; Oliver-Martos B
    Front Immunol; 2021; 12():778204. PubMed ID: 34975865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
    Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
    Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inventory of short term and long term changes in gene expression under interferon β treatment of relapsing remitting MS patients.
    Paap BK; Hundeshagen A; Hecker M; Zettl UK
    Curr Pharm Des; 2012; 18(29):4475-84. PubMed ID: 22612748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.
    Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Capobianco M; Bertolotto A
    Mult Scler; 2006 Feb; 12(1):47-57. PubMed ID: 16459719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression analysis of interferon-beta treatment in multiple sclerosis.
    Sellebjerg F; Datta P; Larsen J; Rieneck K; Alsing I; Oturai A; Svejgaard A; Soelberg Sørensen P; Ryder LP
    Mult Scler; 2008 Jun; 14(5):615-21. PubMed ID: 18408020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.